{"prompt": "['OSTPDL1', 'Page 28 of 60', '5.2.1 Severe Hypersensitivity Reaction', 'Hypersensitivity reactions must be treated according to best medical', 'practices. Patients should also be instructed to report any delayed', 'reactions to the investigator immediately:', 'a. Symptoms: Impaired airway, decreased oxygen saturation (<92%),', 'confusion, lethargy, hypotension, pale/clammy skin, cyanosis', 'b. Management: epinephrine injection, dexamethasone (or equivalent)', 'infusion, continuous monitoring, and potential ICU management', 'Patients who experience an acute severe hypersensitivity reaction should', 'no longer receive avelumab therapy.', '5.2.2 Influenza-Like Symptoms', 'For prophylaxis of influenza-like symptoms, patients may receive a non-', 'steroidal anti-inflammatory drug (NSAID) such as ibuprofen 10mg/kg', '(MAX 800 mg) or naproxen sodium 10mg/kg (MAX 500 mg) may be', 'administered 2 hours before and 8 hours after the start of each avelumab', 'infusion.', '5.2.3 Tumor Lysis Syndrome', 'Because avelumab can induce ADCC, there is a potential risk of tumor', 'lysis syndrome. Should this occur, participants should be treated as per', 'local guidelines for tumor lysis syndrome including IV fluids, frequent', 'monitoring of electrolytes (uric acid, K+, Ca++, PO4), and use of', 'allopurinol or rasburicase as needed.', '5.3', 'Management of Immune-Mediated Adverse Reactions', 'Since inhibition of PD-L1 stimulates the immune system, immune-related', 'AEs (irAEs) may occur. Treatment of irAEs is mainly dependent upon', 'severity (NCI-CTCAE grade):', 'Grade 1 to 2: treat symptomatically or with moderate dose steroids,', 'more frequent monitoring.', 'Grade 1 to 2 (persistent): manage similar to high grade AE (Grade 3', 'to 4)', 'Grade 3 to 4: treat with high dose corticosteroids', 'Treatment of gastrointestinal, dermatological, pulmonary, hepatic and', 'endocrine irAEs should follow guidelines set forth below.', 'For Grade 2 toxicities requiring delay of avelumab therapy as listed in the', 'tables below, study drug should be held until < Grade 1. Patients who', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 29 of 60', 'experience Grade 2 toxicities that do not resolve to < Grade 1 despite', 'symptomatic/medical intervention within 14 days should have study drug', 'discontinued; in the setting of clinical benefit, investigators may discuss', 'continuation of study drug with the PI on a case-by-case basis.', 'Gastrointestinal irAEs', 'It is recommended that colitis or enterocolitis of Grade 1 be evaluated for other', 'non-immune mediated causes, then monitored closely and treated', 'symptomatically without steroids, including a trial of loperamide may be used. For', 'Grade 2 colitis or enterocolitis, recommendations include endoscopy. Even if', 'colonoscopy does not reveal gross findings of colitis, biopsies should be', 'performed and strong consideration should be given to upper endoscopy and', 'biopsies. Patients with gross or biopsy proven colitis or enteritis should receive IV', 'steroids (recommend 1 mg/kg methylprednisone daily X 7 days) followed by a', 'minimum 30 day taper. In patients with Grade 3 or 4 enterocolitis that does not', 'respond to high dose steroids after 7 days, further therapies should be', 'administered as clinically indicated in consultation with gastroenterology', 'subspecialists.', 'Concern for immune-mediated liver toxicity may be elicited following hepatic', 'enzyme (AST, ALT) elevation of 3-fold over baseline and/or right upper quadrant', 'abdominal pain or unexplained nausea or vomiting. Other etiologies for', 'transaminitis should be considered and evaluated and may include but are not', 'limited to neoplastic, concurrent medications, viral hepatitis, and other toxic', 'etiologies. Evaluation for autoimmune etiologies may be evaluated by ANA, pANC,', 'and anti-smooth muscle antibody tests as well as hepatology consultation with', 'possible biopsy.', 'Pancreatitis has rarely been associated with checkpoint inhibitors and should be', 'considered in cases of abdominal pain associated with elevations of amylase and', 'lipase. Treatment of pancreatitis should be supportive and may include', 'consultation with gastroenterology subspecialists. Grade 3 or 4 amylase or lipase', 'abnormalities that are not associated with diabetes mellitus, associated liver or', 'gallbladder inflammation, or clinical manifestations of pancreatitis and which', 'decrease to Grade 2 within 7 days will not require discontinuation of avelumab.', 'Any patient experiencing diarrhea (which may be defined as watery stool, or', 'increase in the frequency stools above grade 1 with urgency or nocturnal bowel', 'movement, or melena or hematochezia) should be further evaluated for etiology', 'that should include a search for an infectious etiology, C. Difficile colitis and other', 'alternative infections as clinically indicated. Consideration should be given to', 'discontinuing medications known to exacerbate colitis.', 'Severity of Diarrhea /', 'Management', 'Colitis (NCI-CTCAE', 'Follow-up', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-ARB APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}